Is calcitriol life-protective for patients with chronic kidney disease?

Journal of the American Society of Nephrology

Volumn 20, Issue 11, 2009, Pages 2285-2290

  Thadhani, Ravi ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; CALCITRIOL;

ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; GLUCOSE TOLERANCE; HUMAN; HYPOCALCEMIA; MINERAL METABOLISM; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

CALCITRIOL; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; VITAMINS;

EID: 72049101917     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009050494     Document Type: Article

References (81)

1. Sommer A: 1997 Albert Lasker Award for Clinical Research. Clinical research and the human condition: moving from observation to practice. Nat Med 3: 1061-1063, 1997
2. Sommer A, Tarwotjo I, Hussaini G, Susanto D: Increased mortality in children with mild vitamin A deficiency. Lancet 2: 585-588, 1983
3. Thadhani R: Activated vitamin D sterols in kidney disease. Lancet 371: 542-544, 2008 (Pubitemid 351232019)
4. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266-281, 2007
5. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74: 2136-2143, 1984 (Pubitemid 15197358)
6. Sprague SM, Moe SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 19: 532-539, 1992
7. Malluche HH, Goldstein DA, Massry SG: Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 63: 494-500, 1979
8. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274-279, 1989
9. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998 (Pubitemid 28158000)
10. Holick MF: Resurrection of vitamin D deficiency and rickets. J Clin Invest 116: 2062-2072, 2006
11. Drueke TB: Control of secondary hyperparathyroidism by vitamin D derivatives. Am J Kidney Dis 37: S58-S61, 2001 (Pubitemid 32048025)
12. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003 (Pubitemid 36910023)
13. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005 (Pubitemid 41710323)
14. Mangelsdorf DJ, Pike JW, Haussler MR: Avian and mammalian receptors for 1,25-dihydroxyvitamin D3: In vitro translation to characterize size and hormone-dependent regulation. Proc Natl Acad Sci U S A 84: 354-358, 1987
15. Petkovich M, Brand NJ, Krust A, Chambon P: A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330: 444-450, 1987 (Pubitemid 18006425)
16. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D(3) users in a haemodialysis population. Nephrol Dial Transplant 19: 179-184, 2004 (Pubitemid 38072630)
17. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006 (Pubitemid 44215354)
18. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 70: 351-357, 2006 (Pubitemid 44086585)
19. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70: 1858-1865, 2006
20. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andia JB: Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74: 1070-1078, 2008
21. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168: 397-403, 2008 (Pubitemid 351350586)
22. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19: 1613-1619, 2008
23. Levin A, Djurdjev O, Beaulieu M, Er L: Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 52: 661-671, 2008
24. Shinaberger CS, Kopple JD, Kovesdy CP, McAllister CJ, van Wyck D, Greenland S, Kalantar-Zadeh K: Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 3: 1769-1776, 2008
25. St Peter WL, Li S, Liu J, Gilbertson DT, Arneson TJ, Collins AJ: Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis. Pharmacotherapy 29: 154-164, 2009
26. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, Piera LM, Saran R, Wolfe RA, Port FK: The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24: 963-972, 2009
27. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004-1013, 2007 (Pubitemid 47530570)
28. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75: 88-95, 2009
29. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, Sea MM, Woo J: Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: A 3-y prospective cohort study. Am J Clin Nutr 87: 1631-1638, 2008 (Pubitemid 351872624)
30. Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Camargo CAJ, Melamed M, Norris K, Stampfer M, Powe NR, Thadhani R: Impact of activated vitamin D and race on hemodialysis survival. J Am Soc Nephrol 19: 1379-1388, 2008
31. Shultz TD, Fox J, Heath H III, Kumar R: Do tissues other than the kidney produce 1,25-dihydroxyvitamin D3 in vivo? A reexamination. Proc Natl Acad Sci U S A 80: 1746-1750, 1983 (Pubitemid 13136425)
32. Holick MF, Garabedian M, DeLuca HF: 1,25-dihydroxycholecalciferol: metabolite of vitamin D3 active on bone in anephric rats. Science 176: 1146-1147, 1972
33. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007 (Pubitemid 44967731)
34. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, Raymond NT, Howie AJ, Cockwell P, Stewart PM, Hewison M: Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 74: 1343-1353, 2008
35. Autier P, Gandini S: Vitamin D supplementation and total mortality: A meta-analysis of randomized controlled trials. Arch Intern Med 167: 1730-1737, 2007 (Pubitemid 47403059)
36. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005 (Pubitemid 41058323)
37. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
38. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS: Hypovitaminosis D in medical inpatients. N Engl J Med 338: 777-783, 1998
39. Sommer A, Tarwotjo I, Djunaedi E, West KP Jr, Loeden AA, Tilden R, Mele L: Impact of vitamin A supplementation on childhood mortality. A randomised controlled community trial. Lancet 1: 1169-1173, 1986 (Pubitemid 16122421)
40. Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, Watanabe A, Koizumi J, Takeda R: Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med 305: 478-482, 1981 (Pubitemid 11047414)
41. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994
42. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207, 2008
43. Attar PS, Wertz PW, McArthur M, Imakado S, Bickenbach JR, Roop DR: Inhibition of retinoid signaling in transgenic mice alters lipid processing and disrupts epidermal barrier function. Mol Endocrinol 11: 792-800, 1997 (Pubitemid 27225306)
44. Fuchs E, Green H: Regulation of terminal differentiation of cultured human keratinocytes by vitamin A. Cell 25: 617-625, 1981 (Pubitemid 11000143)
45. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-S119, 1998 (Pubitemid 28527268)
46. Gillor A, Groneck P, Kaiser J, Schmitz-Stolbrink A: [Congestive heart failure in rickets caused by vitamin D deficiency]. Monatsschr Kinderheilkd 137: 108-110, 1989
47. Uysal S, Kalayci AG, Baysal K: Cardiac functions in children with vitamin D deficiency rickets. Pediatr Cardiol 20: 283-286, 1999 (Pubitemid 29279632)
48. Weishaar RE, Simpson RU: Vitamin D3 and cardiovascular function in rats. J Clin Invest 79: 1706-1712, 1987
49. Wu J, Garami M, Cheng T, Gardner DG: 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 97: 1577-1588, 1996 (Pubitemid 26105467)
50. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC: Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288: E125-E132, 2005 (Pubitemid 40023798)
51. Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG: Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 67: 217-226, 2005
52. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290, 1989 (Pubitemid 19202488)
53. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11: 912-916, 2000
54. Gross ML, Ritz E: Hypertrophy and fibrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Semin Dial 21: 308-318, 2008
55. Ritz E, Wanner C: The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 3: 920-929, 2008
56. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 104: 16810-16815, 2007 (Pubitemid 350210947)
57. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E: Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 29: 465-472, 2009
58. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D: Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74: 170-179, 2008 (Pubitemid 351915078)
59. Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU: 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 51: 559-564, 2008
60. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU: Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149: 558-564, 2008 (Pubitemid 351159356)
61. Valdivielso JM, Ayus JC: Role of vitamin D receptor activators on cardiovascular risk. Kidney Int Suppl S44-S49, 2008
62. Levin A, Li YC: Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease?. Kidney Int 68: 1973-1981, 2005
63. Koleganova N, Piecha G, Ritz E, Gross ML: Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant 24: 778-787, 2009
64. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004 (Pubitemid 39031360)
65. Chertow GM: Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol 14: S310-314, 2003
66. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003 (Pubitemid 37098542)
67. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 72: 709-715, 2007 (Pubitemid 47373790)
68. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA: Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19: 1509-1519, 2008
69. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997 (Pubitemid 27494749)
70. Razzaque MS, Lanske B: Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 12: 298-305, 2006
71. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y: Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17: 2393-2403, 2003 (Pubitemid 37542205)
72. Yumita S, Suzuki M, Akiba T, Akizawa T, Seino Y, Kurokawa K: Levels of serum 1,25(OH)2D in patients with pre-dialysis chronic renal failure. Tohoku J Exp Med 180: 45-56, 1996 (Pubitemid 126520935)
73. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD: Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18: 2116-2124, 2007 (Pubitemid 47041077)
74. Ohnishi M, Nakatani T, Lanske B, Razzaque MS: Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 75: 1166-1172, 2009
75. Turk S, Yeksan M, Tamer N, Gurbilek M, Erdogan Y, Erkul I: Effect of 1,25 (OH)2D3 treatment on glucose intolerance in uraemia. Nephrol Dial Transplant 7: 1207-1212, 1992 (Pubitemid 23014448)
76. Mak RH: 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53: 1353-1357, 1998
77. Yeksan M, Turk S, Polat M, Cigli A, Erdogan Y: Effects of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis patients. Int J Artif Organs 15: 704-707, 1992
78. Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campdera F, Perez-Garcia R, Valderrabano F: Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 78: 23-27, 1998 (Pubitemid 28014455)
79. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773, 2006
80. Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA Jr, Koeffler HP, Thadhani R: Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 48: 418-424, 2009
81. Foley RN, Collins AJ: End-stage renal disease in the United States: An update from the United States Renal Data System. J Am Soc Nephrol 18: 2644-2648, 2007 (Pubitemid 47531190)